Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342041 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects
A Phase 1 study of Cognitive Disorders, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT02342041 is a Phase 1 study of Cognitive Disorders that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02342041, a Phase 1 study of Cognitive Disorders, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SUVN-G3031
Study Locations (1)
Kansas
- Quintiles - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342041
The ClinicalTrials.gov registry entry for NCT02342041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cognitive Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02342041 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT02342041 about?
NCT02342041 is a clinical study titled "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects". The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-G3031 in healthy male subjects following single or multiple ascending doses.
What is the current status of trial NCT02342041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2014-09. Estimated completion is 2015-08.
What conditions does trial NCT02342041 study?
This clinical trial studies the following conditions: Cognitive Disorders.
What interventions are being tested in trial NCT02342041?
The interventions under investigation include: Placebo (DRUG), SUVN-G3031 (DRUG).
Who is sponsoring clinical trial NCT02342041?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342041 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.